

CERTIFICATE

Survey of 03 June 2020

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 32 - Edoxaban (505):

Validity 12 months:

Edoxaban


(R) analysis is subject to the RiliBÄK

Participant:
2430
MUDr., PhD. Martin Spacek
Vseobecna fakultni nemocnice v Praze
Centralni hematologicke laboratore ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 07 July 2020



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)